Label-Free Detection – New biosensors facilitate broader range of drug discovery applications
This article highlights some of the findings of a recent market report on labelfree detection trends. In particular, it looks at the current perception, main use and biggest benefit of label-free detection today. It considers the potential of label-free to displace other detection technologies and the impact that label-free might have on enabling access to difficult target classes.
It reviews the latest and emerging developments in label-free detection systems, describes their underlying technology principles and discusses their prospects in enabling higher throughput processing and getting out more information about an interaction from a single experiment. The next generation of label-free tools will predominantly be microplate-based sensors which for the first time may facilitate wider interest in label-free detection, particularly from those involved in primary screening.
Applications enabled by these new label-free tools include cell-based receptor/ligand interactions particularly of orphan receptors; noninvasive cell proliferation and in vitro cytotoxicity testing; and antibody and small molecule affinity analysis.The prospects for label-free detection expanding beyond the market focus and customer niche created by surface plasmon resonance have never looked brighter.
According to a recent pharma market report on label-free (HTStec’s label-free Detection Trends 2004) the majority of respondents surveyed perceive label-free ‘as a promising analytical tool that needs to mature’ (Figure 1).
This maturation process looks set to escalate as several new label-free detection systems are launched over the coming year, facilitating wider exploitation of the technology across the drug discovery process, including, for the first time, those areas that require higher throughput (eg primary screening).
Currently the main use of label-free detection is kinetics (on and off-rate) analysis closely followed by affinity analysis. Most of these analyses are done by secondary screening (Hits-to-Leads) and lead optimisation (Leads-to- Candidate) groups.
Use of label-free today in Yes/No end point screening and specificity testing is minimal in comparison (Figure 2), although this could all change if label-free finally impacts primary screening.
Two-thirds of survey respondents think that being ‘label-free’ was the biggest benefit of label-free detection (Figure 3).
The other main advantages of label-free detection are summarised in Table 1.
Label-free may help address difficult targets
Of the main detection technologies in use today greatest interest was shown by respondents in replacing radioactive and ELISA assays with labelfree (Figure 4).
However, a significant proportion of respondents do not see label-free replacing any of their existing detection technologies. They see label-free as one of several tools that can aid in the characterisation of drug-target interactions and complementary to their existing range of preferred detection techniques. These respondents would even like to see label-free as an additional readout on a multimode reader. If an enabling label-free system were to become available (ie one that matched users’ criteria of sensitivity, cost/well and throughput) survey respondents could envisage a situation where up to a third of their existing primary screens might be replaced by label-free.
HTStec’s report also documents feedback on the impact that label-free detection might have on enabling access to difficult target classes. The findings suggests that on average around one in four targets do not make it to primary screening. The main reasons these ‘difficult targets’ do not get screened is the lack of quality (robust) assay methods available to screen that target or the target in question is an orphan or unvalidated and is given lower priority relative to other targets.
Respondents were split 50:50 as to whether labelfree will help them address these difficult targets. Of those who thought label-free might help, an enabling label-free system could potentially address up to one-third of their difficult targets. Protein-protein interactions were seen as one of the main difficult target classes for which existing assay technologies are currently inadequate. Although, receptor-ligand assays were the most investigated molecular interaction, and of greatest interest to survey respondents.
Label-free detection system requirements
Sensitivity and throughput were cited as the biggest limitations to the current widespread use of labelfree detection. In terms of required sensitivity, a label-free system needs to be able to detect the binding of small molecular weight ligand (typically 200-300 Daltons) at a surface mass detection limit of <5pg/mm2 and at 10-9M concentration in the assay buffer.
The throughput required in a label-free system varies with different parts of the drug discovery process, but 5,000 data points/hour (ie about 13 x 384 plates/hour) are needed for primary screening while 200 data points/hour would be acceptable for lead optimisation. The lack of availability of microplate-based label-free systems and Cap-Ex costs were also rated very highly as limiting factors in the deployment of label-free.
The preferred label-free sample carrier format was a microplate-based sensor (384-well) (Figure 5) and the maximum acceptable price for an instrument able to read such plates was no more than $150,000. The median price per data point at which all respondents would consider implementing label-free primary screening was <$0.2 per data point.
Most survey respondents were aware of surface plasmon resonance (SPR) and its use in label-free detection, many were experienced Biacore users. However, awareness of other types of label-free detection, including emerging technologies, was much less evident.
Table 2 summarises and compares some of latest developments in label-free detection, with a particular focus on those systems that will utilise microplate-based sensors.
A more detailed description of these new developments, grouped according to their underlying technology principles, is given below.
Surface plasmon resonance
Biacore (www.biacore.com) was the pioneer and is the world leader in monitoring protein interactions using surface plasmon resonance (SPR) technology. Most people associate label-free detection with SPR and Biacore instruments. SPR is a phenomenon that occurs in a thin metal film at an optical interface under conditions of total internal reflection and is observed as a decrease or dip in reflected light intensity at a specific angle. The system uses polarised light and can detect subtle changes in optical resonance that occur when molecules bind to or dissociate from an immobilised target biomolecule.
Essentially, SPR detects changes in mass of dissolved material in the aqueous layer close to the sensor surface by measuring changes in refractive index (SPR angle). Over the years Biacore has offered a range of systems designed to study the interaction of a protein with other molecules, typically another protein or a small molecule drug. Systems have been configured to meet the demands of performance and regulatory support, as these vary through the drug discovery process: from early research to lead characterisation, through to clinical immunogenicity studies and inprocess quality control of biopharmaceuticals.
The latest system, Biacore T100™, will be introduced in Q1 2005. This instrument represents the next generation of protein interaction analysis systems from Biacore. The company has seen an increasing use of their technology throughout the drug discovery process. The ability to gain unique data about the interaction of proteins, with other proteins or with low molecular weight molecules, has enabled faster, better decisions which in turn has improved productivity, for example, by earlier elimination of sub-optimal compounds or by facilitating selection of the most likely potential biotherapeutics.
To significantly improve on ease of use compared to earlier systems, the Biacore T100™ uses software wizards, built upon the years of experience within Biacore, to assist at every step of an analysis from method development through to data evaluation. This ensures that interactions are performed and interpreted in the best possible way. An additional feature which further enhances data quality is the stability of this system at higher temperatures.
Studying interactions at 37°C rather than room temperature will give far greater insight into the potential behaviour of a molecule in vivo, again shortening the decision process for selection of potential biotherapeutics. To ensure compliance with regulatory demands both the hardware and software of the Biacore T100™ have been designed for 21 CFR Part 11 compliance. A GLP/GMP support package is available to save time during the otherwise time-consuming validation process.
Biacore has never positioned itself to address the primary screening segment of drug discovery. The launch of Biacore T100™ reaffirms the company’s focus on higher content and data quality ie getting out more information about an interaction from a single experiment, like kinetics, affinity, specificity, concentration and even thermodynamic information, in order to make better, faster decisions.
Guided mode resonance
SRU BIND™ (Biomolecular Interaction Detection) from SRU Biosystems (www.srubiosystems.com) is a novel optical biosensor that is ready for use in drug discovery applications. SRU BIND™ is based upon the optical principle known as guided mode resonance. The biosensor incorporates a proprietary nanostructure replicated on to a plastic substrate, enabling the high-volume manufacture of optical biosensors in a microplate format. BIND sensors are designed so that when a collimated linearly- polarised beam of broad-spectrum light is incident on the sensor, a narrow wavelength light beam is reflected directly back to the BIND Reader.
Binding interactions on the biosensor are detected as a shift (increase) in the wavelength of this directly reflected beam. Due to the subwavelength structures that are part of the biosensor, rainbow colours are observed on the biosensor in regular laboratory light, even though the resonance reflection is in the infrared.
The SRU BIND™ system consists of single-use biosensor plates in industry-standard formats (96- well or 384-well configuration) and the BIND Plate Reader. A 384-well plate can be read in approximately one minute, while a 96-well plate requires as little as 15 seconds. The BIND Reader has been designed to interface with robotics for automated plate-handlers or liquid-dispensing robots. The wide dynamic range of the BIND sensor allows quantitative analysis of cells, macromolecules, DNA and small molecules. BIND will replace existing label-free systems that suffer from a lack of throughput when performing affinity analysis. In addition, SRU BIND will be a powerful tool in combination with existing labelled methods, providing multi-mode readouts and biological system analysis.
Over the past 12 months, SRU Biosystems has worked with multiple beta site users. A primary application focus of the BIND system has been quantitative analysis or affinity ranking when hundreds to thousands of samples need to be processed. For example, the BIND system can be used to perform direct binding assays for large or small molecules in secondary screening and lead optimisation. Sensitivity and throughput of the system meet the needs for the next generation of labelfree analysis. The system was commercially available from Q4 2004. Instruments will be available at a US list price of $150,000. BIND microplates are expected to cost less than $100 each. Plates come pre-packaged and derivatised to offer the user a variety of attachment methods of the target to the biosensor.
Resonant waveguide grating sensors
Corning Life Sciences (www.corning.com) is developing a label-free detection platform for drug screening called the Epic™ System. The Epic™ System allows researchers to explore biomolecular interactions in a direct, label-free, high-throughput manner.
The system consists of the following:
1) a disposable 384-well microplate (SBS standard) with optical sensors and attachment surface chemistry inside each well;
2) an HTS-compatible microplate reader that is capable of reading 40,000 wells per eight hours; and
3) a set of label-free, direct binding assay protocols.
The optical sensors (the square region in the picture) in each well of Corning’s microplate are resonant waveguide grating sensors. When illuminated with broadband light, these sensors reflect only a specific wavelength that is a sensitive function of the index of refraction close to the sensor surface. The sensors are coated with a surface chemistry layer that enables covalent attachment of protein targets via a primary amine group. After a target is immobilised, a baseline reading is established (Figure 1).
When the binding assay is performed and analyte molecules bind to the immobilised target, a change in the local index of refraction is induced, and results in a shift in the wavelength of light that is reflected from the sensor (Figure 2).
The magnitude of this wavelength shift is proportional to the amount of analyte that binds to the immobilised target. The entire process is label-free and requires only the binding partners of interest.
With its 384-well microplate format the Epic™ System will enable researchers to screen compounds in a high-throughput manner that is compatible with existing automation in HTS labs. Because the binding assay involves only the target protein and drug candidate, assay development is simple and straightforward. In its most basic format, Epic™ assays consist of the immobilisation of a target protein on the sensor surface followed by wash-free binding assays using potential drug candidates. Some examples of application for this universal platform include small-molecule/protein assays, protein/DNA interactions, antibody/antigen interactions, kinase direct bind and functional assays, and cytokine/cytokine receptor assays.
A major advantage of these direct bind assays performed on the Epic™ System is the ability to screen orphan receptors (receptors in which the natural ligand is not known). In other words, it will be capable of detecting the binding of a 300 Dalton compound to a 70K Dalton immobilised target with CVs of 10% or less (depending on assay type). In addition, if the immobilised target is smaller (eg 25K Dalton) it is possible to detect the binding of smaller compounds (eg 150 Dalton). The Epic™ System is currently in an Alpha evaluation phase. Corning will initiate a Beta evaluation phase in 2005, followed by a commercial launch.
Evanescent wave sensing
Evanescent wave sensing utilises the evanescent part of an electromagnetic wave to sense a reaction which takes place at the interface where the wave is generated. Evanescent waves can be found in different optical configurations (total internal reflection, surface plasmon mode, waveguide mode, etc). The advantage of this sensing approach is that a part of the propagating guided light, (the evanescent wave), penetrates into the sensing area (where the target and analyte interact) and is affected by optical changes occurring only in this region.
The sensors are based on a resonant structure composed of a substrate (eg plastics, glass, silica); a high refractive index waveguiding layer (eg Ta2O5, TiO2, Si3N4) with grating structures; an immobilised target layer (eg antibodies, DNA, enzyme, proteins etc); and the analyte whose binding is being studied in the medium.
CSEM has developed (www.csem.ch) WIOS (wavelength-interrogated optical sensing) label-free detection technology, which is based on a waveguide grating coupling with wavelength modulation. The wavelength at which the resonant coupling occurs depends on the mass of the target adsorbed to the sensing site. The waveguiding layer is in contact with the target being examined and the interaction takes place through the evanescent part of the waveguide mode. Changes occurring in the evanescent wave as a result of analyte binding to the immobilised target result in a change in the resonance wavelength.
By monitoring the resonance wavelength with time, extremely small optical changes at the sample waveguide interface can be observed with high sensitivity. In order to take into account variation which might be introduced by unwanted effects like temperature changes, laser wavelength perturbation and non-specific binding on the sensing sites, one or several sensing sites of the chip can be used as a reference site.
The key features of CSEM’s WIOS instrument are:
1) simultaneous measurement of up to eight channels;
2) fast readout for real-time monitoring (10Hz);
3) detection limit <0.5pg/mm2; and
4) modular optical system which can be adapted either for microplate use or further miniaturised into a chip-based diagnostic system.
WIOS is a market-ready detection platform, which is flexible to address drug discovery, as well as the diagnostic and food technology markets. CSEM is currently searching for licensing, manufacturing and distribution partners of the WIOS technology platform.
MDS Sciex (www.mdssciex.com) is developing a system based on Cellular Dielectric Spectroscopy (CDS), a novel technology that enables comprehensive pharmacological evaluation of endogenous cell surface receptors using a label-free, real-time, kinetic cell-based assay. CDS is a universal assay that allows measurement of multiple types of receptors including G protein-coupled receptors (GPCRs) and tyrosine kinase receptors using the same platform and without the need for any modification of the cell. The unique information generated by CDS allows deconvolution of receptormediated signal transduction, which can be used in characterising GPCRs including orphan GPCRs.
CDS technology is based on the measurement of complex impedance changes (ΔZ). Impedance (Z) is related to the ratio of voltage to current as described by Ohm’s law (Z=V/I). Cells are seeded onto a custom 96-well microplate that contains electrodes at the bottom of the wells. The CDS instrument supplies constant voltage producing a current that flows around and between cells (extracellular current or Iec) and through cells (transcellular current, Itc) (MDS Sciex Figure 1).
CDS measures changes in impedance upon stimulation of different cell surface receptors. Cell stimulation on addition of an agonist or antagonist is achieved using a 96-channel dispense head with adjustable dispense speed, adjustable pipette height and mixing capability. Impedance measurements are made simultaneous with fluid addition, with an update rate of 1sec.
Contributors to the impedance measurements are changes in cell adherence to their substrate, changes in cell shape and volume, and changes in cell-cell interactions. These will affect the flow of extracellular and transcellular current and hence the magnitude and characteristics of the signal measured. Each of these physiological changes can be linked to receptor stimulation through classical signalling pathways that result, for example, in changes in cytoskeletal organisation. MDS Sciex plans to launch the commercial CDS system in late 2005.
ACEA Biosciences (www.aceabio.com) is developing a broad biosensor platform for label-free, real-time analysis of cell-based assays. The RTCES ™ (Real-Time Cell Electronic Sensing) System is ACEA’s first product based on this patented technology platform. The core of the system is the microelectronic cell sensor arrays integrated into the bottom of microtiter plates. RT-CES™ uses a non-invasive impedance-based measurement to detect the presence, absence or change of properties of cells or molecules affecting the electronic properties and ionic passage on the sensor surfaces.
For cell-based assays, cells are grown in the individual, sensor-containing wells of the microtiter plate and placed in a standard incubator. With the user-friendly integrated software, the system can be programmed to collect data as frequently as every minute over virtually any time period. The electronic sensors therefore provide hands-free, continuous, quantitative information concerning the biological status of the cells present in the well. Changes to the biological status of the cells are measured automatically in real-time by the RT-CES™ system. The entire process is noninvasive and harmless to the cells.
ACEA’s RT-CES™ system is ideally suited for the time-dependent, dynamic evaluation of inhibition of cancer cell proliferation and to in vitro cytotoxicity testing in both lead identification and lead optimisation phases of drug development. The ACEA Biosciences RT-CES™ system can also be used to study receptor activation for almost any GPCR target, overcoming traditional assay limitations through its sensitivity to subtle cellular changes, and ability to provide real-time monitoring and kinetic data. The ACEA RT-CES™ system is currently available in 16 and 96-well formats for research applications and assay development. RTCES ™ technology is scalable to 384 or higher, and can be readily adapted to robotic workstations.
Resonant acoustic profiling
Akubio (www.akubio.com) is developing a highly sensitive, real time, label-free molecular interaction analysis system based on piezoelectric technology. Called Resonant Acoustic Profiling (RAP™), the technique measures the changes in oscillation of quartz crystal resonators to give information about the specificity, affinity, kinetics and concentration of molecular binding. Based on the same technology the electronics industry uses for timing devices in everything from cell phones to microwaves, the technology is cost-effective, robust, and very scalable.
During RAP analysis target molecules are attached to the sensor surface through direct linkage or capture. Samples containing potential binding partners are then applied to the sensor surface using either flow-based or static delivery techniques. Frequency and resistance parameters of the crystal oscillation are then measured over time to characterise binding of sample molecules to the surface bound target.
Measurement of the changes in frequency of crystal oscillation provides information about changes in mass at the sensor surface. The RAP technique has already been employed to characterise the binding of compounds as small as a few hundred Daltons and as large as whole cells.
The RAP analysis technique overcomes a number of problems intrinsic to optical based label-free analysis methods. Since RAP measures the change in molecular mass attached to the sensor surface, changes in fluid environment have minimal effect on binding measurements. Analyses of samples in media such as serum and ascities fluid, as well as in organic solvents, cause little if any artefacts in binding measurements. Also due to the simplicity of the detection method RAP technology is very scalable. Both an 8-channel (RAPid) and a 96-well format instrument (RAPArray) are under development. Akubio currently plans the commercial launch of the RAPid instrument in early 2006 and the RAPArray system in early 2007.
ForteBio (www.fortebio.com) is developing analytical systems capable of providing rapid real-time analysis of biomolecular interactions (eg proteinprotein interactions) in micro-volume sample sizes, providing information on affinity, kinetics and concentration. ForteBio utilises proprietary biolayer interferometry (BLI) that enables self-calibration and measurement of molecular interactions using simple-to-use and inexpensive instrumentation. The entire analysis can be completed within minutes and does not require labelling of either probe or target. ForteBio’s analytical capabilities thus provide greater value in applications where existing methods such as HPLC, ELISA and surface plasmon resonance (SPR) have limitations in throughput, performance and cost.
What is evident from the new product developments described in this article is that the underlying core technologies of some the microplate-based sensors are in fact quite similar. For example MDS Sciex CDS and ACEA Biosciences RT-CES™ are both based on impedance measurements. The ACEA approach essentially allows for cell-based assays to be performed just like doing cell culture but on electronic plate, plus the entire course of the experiment is monitored with the electronic plate inside the incubator.
MDS’ approach is more like a ‘FLIPR’ method, where cells are cultured on an electronic plate, and then transferred to their reading instrument which has integrated fluidics for compound addition. MDS is capable of monitoring cellular activation at one-second intervals with a total assay time of less than 10 minutes, while ACEA operates with 60-second updates over many hours. ACEA’s initial focus seems to be on cancer biology with an emphasis on cell proliferation and cytotoxicity. MDS is focused on activation of endogenous cellular receptors, aimed at groups performing hit confirmation, potency ranking of ligands and ligand selectivity analysis.
In addition, SRU Biosystems’ BIND™, Corning’s Epic™ and CSEM’s WIOS™ also have similarities in that they all utilise a type of optical resonant reflection and have biosensors based on diffraction gratings. It is also these optical systems that in the short term appear to offer the greatest potential, not only in terms of the diversity of label-free applications enabled, but also from a high throughput processing perspective.
The pricing of the disposable microplate-based sensor will also be critical to the future success and impact of label-free. Customers’ expectations are high that label-free will bring with it some sort of cost premium (ie savings derived from not having to buy labelled reagents and isotopes) and on average respondents indicated that a 40% cost reduction in current screening costs per well would be required in order to make them switch primary screening to an enabling label-free technology. This means that it will not be enough just to swap current reagents costs for the price of a 384-sensor microplate if technology developers want label-free to be used for more than just difficult or orphan targets.
The market survey concluded that label-free detection is expected to make the biggest impact on secondary screening (Hits-2-Leads), lead optimisation (Leads-2-Candidates) and antibody development over the next one to two years. After three years label-free will impact more on secondary screening, and start to become more widely used in primary screening. However, it is predicted that it will take five years for label-free to become a mainstream primary screening technology.
A model was developed to predict the size of the label-free pharma primary screening market. It was estimated that after three years (2007) label-free detection could have captured up to a 4.2% share of the total primary screening market, valued at around $100 million from the sales of instruments and consumables (a label-free sensor plate). It was assumed that only a 384 plate-based label-free sensor will gain sufficient market acceptance to achieve the models predicted sales potential.
The next one to two years will be something of a watershed for label-free detection as the new technology developments described in this article mature and start to be used throughout drug discovery. It will be interesting to see the extent to which these new tools are adopted by end users; the outcome of ongoing IP disputes; the extent to which emerging products may get consolidated within the portfolios of major life science tools providers; and if any of the predictions made in the market survey for label-free hold up.
This article originally featured in the DDW Winter 2004 Issue
John Comley is Managing Director of HTStec Limited an independent market research consultancy whose focus is on assisting clients delivering novel enabling platform technologies (liquid handling, laboratory automation, detection instrumentation and assay reagent technologies) to drug discovery. Further information on accessing the market report ‘Label-free Detection Trends 2004’ can be obtained by visiting www.htstec.com or e-mail email@example.com to receive a free copy of the Report’s Executive Summary and Table of Contents.